Pull up Eli Lilly’s TRIUMPH-1 Phase 3 press release and read the topline: retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, delivered “powerful and clinically meaningful weight loss” in adults with obesity or overweight with at least one comorbidity. Now read the Nature Reviews Drug Discovery signal published this month: incretin-based multi-agonism does not just reduce weight — it reverses obesity and diabetes. Those two words are doing enormous commercial work. “Reduction” is a maintenance story. “Reversal” is a cure narrative, and cure narratives command a different reimbursement conversation entirely.
The market the street has been pricing operates on a simpler assumption: semaglutide and tirzepatide own the decade, biosimilar erosion begins around Novo Nordisk’s compound patent expiry on December 5, 2031, and everyone else is playing for second place. That assumption is now structurally incomplete.
The Duopoly Has an Expiration Date
Novo Nordisk’s semaglutide franchise generated approximately USD $29.3 billion in 2024, representing 70% of total company revenue across Ozempic, Rybelsus, and Wegovy. That is not a product line — that is a single-molecule existential dependency. Eli Lilly’s tirzepatide, sold as Zepbound for weight management and Mounjaro for diabetes, is eating into that lead quarter by quarter. The SURMOUNT-1 trial established tirzepatide’s superiority profile in 72-week obesity data, and Lilly’s self-pay pricing strategy — Zepbound single-dose vials starting at $299 per month through LillyDirect as of December 2025 — is explicitly designed to outflank payer resistance and build volume before the reimbursement infrastructure catches up.
But both of these stories are dual-agonist or single-agonist stories. Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 combination, and the glucagon arm is doing something the existing class cannot: it drives hepatic fat mobilization and resting energy expenditure in a way that pushes efficacy into territory that sounds less like “metabolic management” and more like metabolic reset. That is the mechanistic basis for the “reversal” language in Nature Reviews — and it is the commercial basis for why retatrutide’s Phase 3 data should be read as a category discontinuity, not a line extension.
The global anti-obesity medication market is projected to reach USD $77.24 billion by 2030, growing at a 31.66% CAGR from a $6.62 billion base in 2023. At that growth rate, the question for every player in this space has shifted from “can we get a GLP-1 approved?” to “will our mechanism be differentiated enough to hold price when the market matures?”
Who Wins, Who Scrambles
Lilly holds the clearest near-term position. Retatrutide’s TRIUMPH-1 data lands while Lilly already has Zepbound generating commercial momentum, an existing obesity prescriber network, and a manufacturing scale-up underway. If TRIUMPH-1 and its companion diabetes trials convert to an NDA, Lilly arrives at the triple-agonist launch with infrastructure its smaller competitors will spend years building. The risk-adjusted NPV on retatrutide, priced into a market that will be substantially larger by its likely 2027–2028 launch window, is probably the most underleveraged asset on Lilly’s balance sheet right now.
Novo Nordisk’s exposure here is structural, not cyclical. Semaglutide’s patent cliff in 2031 was already a known problem; what changes with triple-agonist data is the competitive replacement cycle. If retatrutide demonstrates reversal — not just reduction — in outcomes trials, payers will have a clinical justification to tier semaglutide below a superior successor years before biosimilar erosion formally begins. Novo’s answer is cagrisema (semaglutide plus cagrilintide, an amylin analogue), currently in Phase 3, which is a dual-mechanism approach but on a different biological axis than glucagon co-agonism. It may be differentiated enough. It may not be fast enough.
The mid-cap and emerging biotech field faces the harshest recalibration. Any company sitting on a Phase 2 GLP-1 single-agonist asset and pitching it as an obesity platform play just had its BD&L leverage reduced. Acquirers with access to triple-agonist data will apply a higher mechanism bar to every in-licensing conversation. The counterintuitive read here: the companies that benefit most from the multi-agonist signal are not the ones trying to compete with it — they are the ones with assets that address what multi-agonists cannot, specifically muscle preservation, cardiovascular outcomes beyond weight loss, and non-alcoholic steatohepatitis at the fibrosis endpoint. Those adjacencies just became acquisition targets at a premium, because the GLP-1 leaders need to extend beyond weight into durable organ-level outcomes to defend against “reversal” framing becoming the new standard of care expectation.
The Signal Decision-Makers Should Be Acting On
If you run BD&L or pipeline strategy at any company with an obesity or metabolic footprint, the Nature Reviews framing of “reversal” is the document to get in front of your medical affairs and payer access teams immediately. The word will migrate from academic literature to formulary committee presentations faster than most launch teams expect. Companies that proactively define what “reversal” means — in terms of biomarkers, durability endpoints, and discontinuation criteria — will shape the reimbursement conversation. Companies that wait for CMS to define it will be responding to a framework they did not write.
The forward signal to watch: Lilly’s full TRIUMPH-1 data presentation at a major metabolic congress, expected in the second half of 2026. The topline confirmed efficacy direction, but the dose-response curve, the responder analysis, and the safety profile at the glucagon receptor arm will determine whether retatrutide’s label can support “reversal” language or gets constrained to the same “chronic weight management” framing that currently caps the category’s reimbursement ceiling. That label negotiation — between Lilly, FDA, and eventually CMS — is the most commercially consequential regulatory conversation in metabolic disease for the next 24 months, and its outcome will tell you exactly how much of that $77 billion market is actually addressable.
References
- Nature Reviews Drug Discovery — “Incretin-based multi-agonist reverses obesity and diabetes”
- Eli Lilly / PR Newswire — “Lilly’s Triple Agonist Retatrutide Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial (TRIUMPH-1)”
- Huateng Pharma — “Semaglutide and Tirzepatide Global Market Share in 2024”
- PubMed / NEJM — “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)”
- Becker’s Hospital Review — “Eli Lilly Reduces Zepbound Price”
- I-MAK — “Semaglutide Patent Expiry Analysis”
- Grand View Research — “Anti-Obesity Medication Market Size & Share Report, 2030”
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
